Therapeutic and subtherapeutic dosing of pregabalin: Medication adherence, healthcare resource utilization, and costs

American Journal of Pharmacy Benefits

Volumn 4, Issue 4, 2012, Pages 158-164

  Sanchez, Robert J ^a   Mardekian, Jack ^a   Clair, Andrew G ^a   Cappelleri, Joseph C ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PREGABALIN;

ADULT; ARTICLE; DIABETIC NEUROPATHY; DRUG COST; FEMALE; FIBROMYALGIA; FOOD AND DRUG ADMINISTRATION; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PAINFUL DIABETIC PERIPHERAL NEUROPATHY; PATIENT COMPLIANCE; POSTHERPETIC NEURALGIA; PROPORTION OF DAYS COVERED; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE;

EID: 84865362228     PISSN: 19454481     EISSN: 21642494     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Hoffman DL, Dukes E. The health status burden of people with fibromyalgia: a review of studies that assessed health status with the SF-36 or the SF-12. Int J Clin Pract. 2008;62(1):115-126.
2. Annemans L, Le Lay K, Taieb C. Societal and patient burden of fibromyalgia syndrome. Pharmacoeconomics. 2009;27(7):547-559.
3. Dworkin RH, Malone DC, Panarites CJ, Armstrong EP, Pham SV. Impact of postherpetic neuralgia and painful diabetic peripheral neuropathy on health care costs. J Pain. 2010;11(4):360-368.
4. Dworkin RH, Panarites CJ, Armstrong EP, Malone DC, Pham SV. Healthcare utilization in people with postherpetic neuralgia and painful diabetic peripheral neuropathy. J Am Geriatr Soc. 2011;59(5):827-836.
5. Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85(3)(suppl):S3-S14.
6. Argoff CE, Backonja MM, Belgrade MJ, et al. Consensus guidelines: treatment planning and options. Mayo Clinic Proc. 2006;81(4):S12-S25.
7. Carville SF, Arendt-Nielsen S, Bliddal H, et al. EULAR evidence based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis. 2008;67(4):536-541.
8. Field MJ, Cox PJ, Stott E, et al. Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc Natl Acad Sci U S A. 2006;103(46): 17537-17542.
9. Lyrica [pregabalin] capsules prescribing information. New York, NY: Pfizer, Inc; April 2009.
10. Gore M, Sadosky A, Tai K-S, Stacey B. A retrospective evaluation of the use of gabapentin and pregabalin in patients with postherpetic neuralgia in usual-care settings. Clin Ther. 2007;29(8):1655-1670.
11. Gore M, Sadosky AB, Zlateva G, Clauw D. Clinical characteristics, pharmaco-therapy and healthcare resource use among patients with fibromyalgia newly prescribed gabapentin or pregabalin. Pain Pract. 2009;9(5):363-374.
12. Gore M, Sadosky A, Zlateva G, Clauw D. Initial use of pregabalin, patterns of pain-related pharmacotherapy, and healthcare resource use among older patients with fibromyalgia. Am J Manag Care. 2010;16(suppl):S144-S153.
13. Sun P, Zhao Y, Zhao Z, Watson P. Medication dosing patterns associated with duloxetine and pregabalin among patients with fibromyalgia. Curr Med Res Opin. 2011;27(9):1793-1801.
14. Wu N, Chen S, Boulanger L, Fraser K, Bledsoe SL, Zhao Y. Duloxetine compliance and its association with healthcare costs among patients with diabetic peripheral neuropathic pain. J Med Econ. 2009;12(3):192-202.
15. Chen SY, Wu N, Boulanger L, Fraser KA, Zhao Y. The relationship between average daily dose, medication adherence, and health-care costs among diabetic peripheral neuropathic pain patients initiated on duloxetine therapy. Pain Pract. 2010;10(6):530-539.
16. Wu N, Chen S, Boulanger L, Rao P, Zhao Y. Average daily dose, medication adherence, and healthcare costs among commercially-insured patients with fibromyalgia treated with duloxetine. Curr Med Res Opin. 2011;27(6):1131-1139.
17. Zhao Y, Chen SY, Wu N, Fraser KA, Boulanger L. Medication adherence and healthcare costs among fibromyalgia patients treated with duloxetine. Pain Pract. 2011;11(4):381-391.
18. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 2007;10(1):3-12.
19. McCullagh P, Nelder J. Generalized Linear Models. 2nd ed. Boca Raton, FL: Chapman and Hall/CRC; 1989.
20. Kleinbaum DG, Klein M. Survival Analysis: A Self-Learning Text. 2nd ed. New York, NY: Springer; 2006.
21. Golay A. Pharmacoeconomic aspects of poor adherence: can better adherence reduce healthcare costs? J Med Econ. 2011:14(5):594-608.
22. Zhao Y, Sun P, Watson P. Medication adherence and healthcare costs among patients with diabetic peripheral neuropathic pain initiating duloxetine versus pregabalin. Curr Med Res Opin. 2011;27(4):785-792.
23. Zhao Y, Sun P, Watson P, Mitchell B, Swindle R. Comparison of medication adherence and healthcare costs between duloxetine and pregabalin initiators among patients with fibromyalgia. Pain Pract. 2011;11(3):204-216.
24. van Seventer R, Feister HA, Young JP. Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. Current Medical Research and Opinion. 2006; 22(2):375-384.